Findings report high baseline eosinophil count and low RDW increase risk of severe immune-related adverse events during therapy, suggesting new monitoring strategies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Acar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: